Methodological and reporting rigor in noninferiority and equivalence trials for multimodality cancer treatment: lessons from breast cancer radiotherapy.
Shi-Jia Wang, Chun-Nan Liu, Yu Tang, Hao Jing, Hui Fang, Yi-Rui Zhai, Si-Ye Chen, Guang-Yi Sun, Xu-Ran Zhao, Yu-Chun Song, Yong-Wen Song, Yue-Ping Liu, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Wen-Wen Zhang, Julia R White, Ye-Xiong Li, Shu-Lian Wang, Chen Hu
J Clin Epidemiol 189 112012
摘要
摘要
OBJECTIVES: To investigate the methodological and reporting quality of noninferiority (NI) or equivalence trials in breast cancer radiotherapy, providing suggestions for future NI/equivalence trials. STUDY DESIGN AND SETTING: Prospective phase III randomized controlled trials comparing different radiation modalities in breast cancer and designed as NI/equivalence were identified. Extracted data included the trial design, analysis, and reporting characteristics. The relationship between trial numbers and publication year was assessed. Trials with prespecified NI margins as absolute risk differences (ARDs) were reevaluated using margins as relative risks. RESULTS: Twenty-one studies were included. The number of publications increased over time. Trial interventions mainly involved dose fractionation and radiation volume. The primary end point was local or locoregional recurrence in 15, toxicity in 5, and both in 1 study. Reporting gaps included the following: not specifying the trial as NI/equivalence in the title/abstract (n = 6); inadequate justification for the NI/equivalence design rationale (n = 10) or margins (n = 12); absence of both intention-to-treat and per-protocol analysis (n = 12); and no reporting of P values for NI/equivalence tests (n = 12) or margins with CIs (n = 5). Fifteen studies failed to meet their planned accrual target, mostly owing to overestimation of event rates in the control group. Among 8 trials with 9 comparisons claiming NI with prespecified margins as ARDs, 4 comparisons were classified as inconclusive when using the margins as relative risks. CONCLUSION: Recently, NI/equivalence trials have dramatically increased in breast cancer radiotherapy; however, there is substantial room for improvement in their methodological and reporting quality.
KM 提取结果
0 个 Figure · 0 个 KM 面板